Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

289
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
289
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

486
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
486
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

353
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
353
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

656
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
656
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

188
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
188
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

252
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
252

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the 'second brain': the gut microbiota as a constitutive co-constructor of embodied cognitive network.

Frontiers in neuroscience·2026
Same author

Functional brain network topological properties in cognitive subgroups of first-episode drug-naïve major depressive disorder.

Journal of affective disorders·2026
Same author

How gut microbiota contribute to neuropsychiatric disorders: evidence from neuroimaging studies.

Frontiers in microbiology·2026
Same author

Biological subtypes of cognitive impairment in first-episode medication-naïve MDD linking individualized functional connectome, cognition, and symptom.

Journal of affective disorders·2026
Same author

Glucosylceramide regulates depression through activating peroxisome proliferator-activated receptor gamma in dorsal striatum.

Theranostics·2026
Same author

Discovery of a novel tau PET tracer: Design, synthesis, radio-labeling, and preclinical evaluations.

European journal of medicinal chemistry·2026

Related Experiment Video

Updated: Aug 7, 2025

Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment
08:33

Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment

Published on: November 17, 2018

13.1K

Interactions Between Antidepressants and Intestinal Microbiota.

Feiyu Xu1, Qinglian Xie2, Weihong Kuang3,4

  • 1West China School of Medicine, Sichuan University, Chengdu, 610041, China.

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|March 7, 2023
PubMed
Summary

The gut microbiome significantly impacts depression treatment by interacting with antidepressants. Understanding these interactions is key for effective depression therapy and developing new microbiome-targeted treatments.

Keywords:
AntidepressantsDepressionInteractionIntestinal microbiotaMetabolism

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

121
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.9K

Related Experiment Videos

Last Updated: Aug 7, 2025

Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment
08:33

Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment

Published on: November 17, 2018

13.1K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

121
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.9K

Area of Science:

  • Neuroscience
  • Microbiology
  • Pharmacology

Background:

  • The microbiota-gut-brain axis influences human health and diseases, notably depression.
  • Interactions between drugs and intestinal microbiota are complex and crucial for disease treatment.
  • Existing research indicates a significant interaction between antidepressants and the gut microbiota.

Purpose of the Study:

  • To explore the intricate relationship between antidepressants and intestinal microbiota.
  • To elucidate how gut microbiota affects antidepressant efficacy and metabolism.
  • To identify the microbiota-gut-brain axis as a potential therapeutic target for depression.

Main Methods:

  • Review of existing studies on drug-microbiota interactions.
  • Analysis of how gut microbiota composition affects antidepressant pharmacokinetics and pharmacodynamics.
  • Examination of microbiota's role in altering intestinal and blood-brain barrier permeability.

Main Results:

  • Antidepressants can alter the abundance and composition of intestinal microbiota.
  • Gut microbiota influences antidepressant metabolism, affecting drug availability and absorption.
  • Microbiota can modulate blood-brain barrier permeability, impacting drug delivery to the CNS.
  • Bacterial bioaccumulation of drugs without biotransformation represents another interaction.

Conclusions:

  • Intestinal microbiota plays a critical role in the efficacy of antidepressant therapy.
  • Considering the gut microbiome is essential when evaluating antidepressant treatment strategies.
  • The intestinal microbiota presents a promising target for novel depression treatment approaches.